Jaguar Health explores strategic alternatives; crofelemer NDA targeted for rare intestinal failure

Jaguar Health, Inc.

Board initiated process to evaluate strategic alternatives including M&A, partnerships, and licensing to maximize shareholder value.
Process aligns with planned completion of clinical work for NDA submission for crofelemer in rare intestinal failure diseases.
Crofelemer reduced parenteral support by up to 37% in pediatric MVID/short bowel syndrome proof-of-concept trial.
Third-party report estimates global nutritional support market for MVID at ~$1.1B in 2026, growing to ~$1.5B by 2033.
CEO Lisa Conte to update on crofelemer program at Life Sciences Virtual Investor Forum on June 24, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.